UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 16 Source: CRO
- €167.1 million turnover
-
-€10.4 million
profit - 44 employees
-
31st Dec 15 Source: CRO
- €136.4 million turnover
-
€461.9 million
profit - 120 employees
- 8 more years available »
Ranking
By Turnover
(€167.1 million)- 339th in Top Companies
- 39th in Health
- 40th in Pharma
By Employees
(44)- 868th in Top Companies
- 97th in Health
- 82nd in Pharma
-
- 44
- €167.1 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 11:07am VW selects Cubic Telecom to supply Touareg model with technology
- 7:21am GAN raises £7.5m to target US internet sports betting
- 7:06am The race for the ECB presidency is heating up
- 6:30am Potential for 25,000 new pharma jobs, US-China trade deal, and Titanic tourism
- 6:22am Profits at Ryanair soar by 10% to €1.5bn in 2018